Table 1.

Susceptibility of enterococci to antibiotic agents in multicentre, comparative studies worldwide

					Daptomycin		Linezolid		Vancomycin		Quinupristin/dalfopristin
Study year	Region	Source of isolates	Enterococcus species	No. of isolates	MIC90	% susceptibility	MIC90	% susceptibility	MIC90	% susceptibility	MIC90	% susceptibility	Reference
2006	USA	bacteraemia, wound or other infections	enterococci	547	2	99.8	2	97.4	>16	71.7	>2	31.1	8
2004–05	Europe	various infection types	VSE	484	4	100	2	99.8	0.5	99.8	ND	ND	9
			VRE	195	4	100	2	100	≥64	21.7	ND	ND
2007	Europe	various infection types	VSE	542	4	100	2	95.4	0.5	100	ND	ND	9
			VRE	187	4	100	2	95.7	≥64	21.4	ND	ND
2005–07	Europe	bloodstream, skin or other infections	VSE										15
			E. faecium	853	2	100	2	99.8	1	100	>2	70.6
			E. faecalis	2133	1	100	2	100	2	100	>2	0.9
			VRE
			E. faecium	267	2	100	2	99.3	>16	0	>2	78.3
			E. faecalis	18	1	100	2	100	>16	0	>2	0
2002–05	USA/Canada	various infection types	VSE	3336	2	99.9	2	99.8	ND	ND	>2	11.2	14
			VRE	1560	4	99.4	2	98.5	ND	ND	2	86.9
2005–08	Europe	bloodstream infections	vancomycin-resistant E. faecium	134	2	99.3	2	98.5	ND	ND	>2	73.1	16
2005–06	Canada	various infection types in ICU patients	E. faecalis	91	1	100	2	92.3	2	97.8	ND	ND	17
			E. faecium	29	2	100	8	34.5	>64	72.4	ND	ND
			VRE	17	1	100	4	64.7	>64	0	ND	ND
			other enterococci	135	1	100	2	97.2	2	94.7	ND	ND
2007–08	USA/Korea	blood or skin infections	E. faecalis (USA/Korea)	455	2	100	2	96.9	4	96.0	32	0.9	13
			E. faecium (Korea)	184	4	100	2	95.7	>128	73.4	4	78.8
			E. faecium (USA)	205	4	98.5	4	85.9	>128	20.0	2	71.7

ICU, intensive care unit; ND, not determined; VRE, vancomycin-resistant enterococci; VSE, vancomycin-susceptible enterococci.

All MIC data were measured using broth microdilution.